Patents by Inventor Dasa Lipovsek

Dasa Lipovsek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for the selection of binding proteins
    Patent number: 10150962
    Abstract: This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mRNA display and yeast surface display in a way that takes advantage of the desirable attributes of both processes.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 11, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventor: Dasa Lipovsek
  • FAST-OFF RATE SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20180258158
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: September 22, 2016
    Publication date: September 13, 2018
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard KRYSTEK, Jr., Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Juhi JUNEJA
  • Modified FGF-21 Polypeptides and Uses Thereof
    Publication number: 20180243375
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Application
    Filed: May 15, 2018
    Publication date: August 30, 2018
    Inventors: Paul E. Morin, Daniel Cohen, Ranjan Mukherjee, Timothy P. Reilly, Rose C. Christian, Dasa Lipovsek, Ray Camphausen, John Krupinski
  • MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF
    Publication number: 20180222960
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 9, 2018
    Inventors: Gene M. DUBOWCHIK, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
    Publication number: 20180201665
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 19, 2018
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Fibronectin based scaffold domain proteins that bind PCSK9
    Patent number: 9856309
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: January 2, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN
    Publication number: 20170354718
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Application
    Filed: April 19, 2017
    Publication date: December 14, 2017
    Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO, Alexander T. KOZHICH, Martin J. CORBETT
  • PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS AND OTHER BINDING PROTEINS
    Publication number: 20170334958
    Abstract: Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands.
    Type: Application
    Filed: May 1, 2017
    Publication date: November 23, 2017
    Inventors: Dasa LIPOVSEK, Richard W. Wagner, Robert G. Kuimelis
  • PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS AND OTHER BINDING PROTEINS
    Publication number: 20170275342
    Abstract: Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands.
    Type: Application
    Filed: February 23, 2017
    Publication date: September 28, 2017
    Inventors: Dasa LIPOVSEK, Richard W. WAGNER, Robert G. KUIMELIS
  • Fibronectin binding domains with reduced immunogenicity
    Patent number: 9765132
    Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: September 19, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jonathan Davis, Dasa Lipovsek, Ray Camphausen
  • NOVEL PD-L1 BINDING POLYPEPTIDES FOR IMAGING
    Publication number: 20170258948
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Application
    Filed: November 24, 2015
    Publication date: September 14, 2017
    Inventors: Paul E. MORIN, David DONNELLY, Dasa LIPOVSEK, Jochem GOKEMEIJER, Maria N. JURE-KUNKEL, David FABRIZIO, Martin C. WRIGHT, Douglas DISCHINO, Samuel J. BONACORSI, Jr., Ralph Adam SMITH, Virginie LAFONT, Daniel COHEN
  • MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF
    Publication number: 20170189486
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 6, 2017
    Inventors: Paul E. MORIN, Daniel COHEN, Ranjan MUKHERJEE, Timothy P. REILLY, Rose C. CHRISTIAN, Dasa LIPOVSEK, Ray CAMPHAUSEN, John KRUPINSKI
  • STABILIZED FIBRONECTIN BASED SCAFFOLD MOLECULES
    Publication number: 20170183393
    Abstract: Provided herein are proteins comprising a fibronectin based scaffold (FBS) domain, e.g., 10Fn3 molecules, that bind specifically to a target, and wherein the FBS domain is linked at its C-terminus to a region consisting of PmXn, wherein P is proline, X is any amino acid and wherein n is 0 or an integer that is at least 1 and m is an integer that is at least 1, and wherein the PmXn moiety provides an enhanced property to the FBS domain, e.g., enhanced stability, relative to the protein that is not linked to the PmXn moiety.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 29, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventor: Dasa LIPOVSEK
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20170174748
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 22, 2017
    Inventors: Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Rex PARKER, Ray CAMPHAUSEN, Jonathan DAVIS, David FABRIZIO
  • Fibronectin based scaffold domain proteins that bind to myostatin
    Patent number: 9662373
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: May 30, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Alexander T. Kozhich, Martin J. Corbett
  • FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY
    Publication number: 20170137494
    Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 18, 2017
    Inventors: Jonathan DAVIS, Dasa LIPOVSEK, Ray CAMPHAUSEN
  • Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
    Patent number: 9631004
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: April 25, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, Daniel Cohen, Ranjan Mukherjee, Timothy P. Reilly, Rose C. Christian, Dasa Lipovsek, Ray Camphausen, John Krupinski
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN
    Publication number: 20170088602
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Application
    Filed: September 30, 2016
    Publication date: March 30, 2017
    Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO, Hui WEI, Aaron P. YAMNIUK, Vidhyashankar RAMAMURTHY, Alexander T. KOZHICH, Martin J. CORBETT, Stanley Richard KRYSTEK, JR.
  • Protein scaffolds for antibody mimics and other binding proteins
    Patent number: 9605039
    Abstract: Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: March 28, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Dasa Lipovsek, Richard W. Wagner, Robert G. Kuimelis
  • Fibronectin Binding Domains with Reduced Immunogenicity
    Publication number: 20170037109
    Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
    Type: Application
    Filed: August 15, 2016
    Publication date: February 9, 2017
    Inventors: Jonathan DAVIS, Dasa Lipovsek, Ray Camphausen